CANCER BIOLOGY

Reproducibility project yields muddy results

An ambitious effort to replicate cancer studies is provoking controversy.

BY MONYA BAKER AND ELIE DOLGIN

Erkki Ruoslahti was on track to launch a drug trial in people with cancer this year, but his plan may now be in jeopardy. A high-profile project designed to gauge the reproducibility of findings from dozens of influential papers on cancer biology publishes results for its first five papers this week, including one by Ruoslahti. And scientists who tried to replicate his findings say that they can't get his drug to work. For the other four papers, the replication results are less clear.

Ruoslahti, a cancer biologist at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California, disputes the verdict on his research. After all, at least ten laboratories in the United States, Europe, China, South Korea and Japan have validated the 2010 paper¹ in which he first reported the value of the drug, a peptide designed to penetrate tumours and enhance the cancer-killing power of other chemotherapy agents. "Have three generations of postdocs in my lab fooled themselves, and all these other people done the same? I have a hard time believing that," he says.

A single failure to replicate results does not prove that initial findings were wrong — and shouldn't put a stain on individual papers, says Tim Errington, the manager of the reproducibility project, who works at the Center for Open Science in Charlottesville, Virginia. Investigators should take results as information, not condemnation, says Errington. "If we just see someone else's evidence as making it hard for the person who did the original research, there is something wrong with our culture."

But Ruoslahti worries that the failure to reproduce his results will weaken his ability to raise money for DrugCendR, a company in La Jolla that he founded to develop his therapy. "I'm sure it will," he says. "I just don't know how badly."

REPEATED ATTEMPTS

The Reproducibility Project: Cancer Biology launched in 2013 as an ambitious effort to scrutinize key findings in 50 cancer papers published in *Nature*, *Science*, *Cell* and other high-impact journals. It aims to determine what fraction of influential cancer biology studies are probably sound — a pressing

Dozens of papers reporting efforts to attack cancer cells are being checked in an open-source project.

question for the field. In 2012, researchers at the biotechnology firm Amgen in Thousand Oaks, California, announced that they had failed to replicate 47 of 53 landmark cancer papers². That was widely reported, but Amgen has not identified the studies involved.

The reproducibility project, by contrast, makes all its findings open — hence Ruoslahti's discomfort. Two years in, the project downsized to 29 papers, citing budget constraints among other factors: the Laura and John Arnold Foundation in Houston, Texas, which funds the project, has committed close to US\$2 million for it.

Full results should appear by the end of the year. But seven of the replication studies are now complete, and *eLife* is publishing five fully analysed efforts on 19 January.

These five paint a muddy picture. Although the attempt to replicate Ruoslahti's results failed³, two of the other attempts^{4,5} "substantially reproduced" research findings — although not all experiments

met thresholds of statistical significance, says Sean Morrison, a senior editor at *eLife*. The remaining two^{6,7} yielded "uninterpretable results", he says: because of problems with these efforts, no clear comparison can be made with the original work.

"For people keeping score at home, right now it's kind of two out of three that appear to have been reproduced," says Morrison, who studies cancer and stem cells at the University of Texas Southwestern Medical Center in Dallas.

Nature spoke to corresponding authors for all of the original reports. Some praised the reproducibility project, but others worried that the project might unfairly discredit their work. "Careers are on the line here if this comes out the wrong way," says Atul Butte, a computational biologist at the University of California, San Francisco, whose own paper was mostly substantiated by the replication team.

The reason for the two "uninterpretable" results, Morrison says, is that things went wrong with tests to measure the growth of tumours in the replication attempts. When this happened, the replication ►

STANLEY FLEGLER/VISUALS UNLIMITED/SPL

► researchers — who were either at contract research labs or at core facilities in academic institutions — were not allowed to deviate from the peer-reviewed protocols that they had agreed at the start of their experiments (in consultation with the original authors). So they simply reported the problem. Doing anything else — such as changing the experimental conditions or restarting the work — would have introduced bias, says Errington.

Such conflicts mean that the replication efforts are not very informative, says Levi Garraway, a cancer biologist at the Dana-Farber Cancer Institute in Boston, Massachusetts. “You can’t distinguish between a trivial reason for a result versus a profound result,” he says. In his study, which identified mutations that accelerate cancer formation, cells that did not carry the mutations grew much faster in the replication effort — perhaps because of changes in cell culture. This meant that the replication couldn’t be compared to the original.

DEVIL'S IN THE DETAILS

Perhaps the clearest finding from the project is that many papers include too few details about their methods, says Errington. Replication teams spent many hours working with the original authors to chase down protocols and reagents, in many cases because they had been developed by students and postdocs who were no longer with the lab. Even so, the final reports include long lists of reasons why the replication studies might have turned out differently — from laboratory temperatures to tiny variations in how a drug was delivered. If the project helps to bring such confusing details to the surface, it will have performed a great service, Errington says.

Others think that the main value of the project is to encourage scepticism. “Commonly, investigators take published results at face value and move on without reproducing the critical experiments themselves,” says Glenn Begley, an author of the 2012 Amgen report.

That’s not the case for Albrecht Piiper, a liver-cancer researcher at the University Hospital Frankfurt in Germany. Piiper has replicated Ruoslahti’s work in his own lab⁸. Despite the latest result, he says, he has “no doubt” about the validity of Ruoslahti’s paper. ■ SEE EDITORIAL P.259

1. Sugahara, K. N. *et al. Science* **328**, 1031–1035 (2010).
2. Begley, C. G. & Ellis, L. M. *Nature* **483**, 531–533 (2012).
3. Mantis, C. *et al. eLife* **6**, e17584 (2017).
4. Aird, F. *et al. eLife* **6**, e21253 (2017).
5. Kandela, I. *et al. eLife* **6**, e17044 (2017).
6. Horrigan, S. K. *et al. eLife* **6**, e18173 (2017).
7. Horrigan, S. K. *et al. eLife* **6**, e21634 (2017).
8. Schmithals, C. *et al. Cancer Res.* **75**, 3147–3154 (2015).

PUBLISHING

Gates Foundation demands open access

Global-health charity clashes with leading research journals.

BY RICHARD VAN NOORDEN

One of the world’s most influential global health charities says that the research it funds cannot currently be published in several leading journals, because the journals do not comply with its open-access policy.

Scientists who do research funded by the Bill & Melinda Gates Foundation are not — for the moment — allowed to publish papers about that work in journals that include *Nature*, *Science* and the *New England Journal of Medicine* (NEJM). (*Nature*’s news team is editorially independent of its research team.)

The bar is a result of the Gates Foundation’s policy in support of open access and open data, which was first announced in 2014 but came into force at the beginning of 2017. “Personally, I applaud the Gates Foundation for taking this stance,” says Simon Hay, a Gates-funded researcher who is director of geospatial science at the Institute for Health Metrics and Evaluation in Seattle, Washington. “The overwhelming majority of my colleagues in global health and fellow Gates grantees with whom I have chatted are highly supportive of these developments,” he says.

OPEN-ACCESS CLASH

The foundation, which is headquartered in Seattle, stipulates that the researchers whom it funds must make open their resulting papers and underlying data sets immediately upon publication. And papers must be published under a licence that allows unrestricted reuse — including for commercial purposes.

But some journals do not offer this kind of open-access (OA) publishing. Many of them allow papers to be made free to read after an embargo period, usually of around six months, and let authors upload accepted manuscripts online. But neither policy meets the Gates Foundation’s requirements. And so, for papers submitted from the start of 2017, a few prominent journals are currently off limits to Gates-funded academics.

Dick Wilder, associate general counsel with the charity’s Global Health Program, says that the foundation does not plan to allow exceptions to its policy.

The clash will affect only a few hundred research papers. The foundation typically

sees around 2,000–2,500 papers published each year from its funding, says Wilder, of which 92% are published in journals that comply with its OA policy.

Still, the discussions could result in influential journals making special arrangements with the Gates Foundation to permit OA publishing. If that happens, it would be the first time that journals such as *Nature* and *Science* have allowed a group of scientists an open-access publishing route on the basis of their funding source.

In 2008, many journals were unwilling to accommodate a US National Institutes of Health (NIH) policy, which, at the time, mandated that papers be made freely available no later than 12 months after publication, notes Peter Suber, director of the Harvard Open Access Project and the Harvard Office for Scholarly Communication in Cambridge, Massachusetts. In the end, publishers accommodated the policy, notes Suber, who expects

“Personally, I applaud the Gates Foundation for taking this stance.”

that the Gates policy will draw the same concessions from publishers.

Another private medical funder, the Wellcome Trust in London, UK, also mandates OA publishing. But its policy permits a six-month embargo on making published papers open. When asked whether Wellcome would change its policy if journals were to accommodate the Gates Foundation requirements, its head of digital services, Robert Kiley, said: “We’ll be watching this development closely.”

JOURNALS’ VIEW

A spokesperson for *Nature*’s publisher, Springer Nature, noted that most of its journals already comply with the Gates Foundation policies and that *Nature* and *Nature*-branded titles make it possible to share links to freely access papers through an online reader.

The American Association for the Advancement of Science, which publishes the *Science* family of journals, says that it is “in discussions with the Gates Foundation on this matter”, and the *NEJM* says that “the policy of the Gates Foundation is under active discussion”. ■